The Union Ministry of Health and Family Welfare in India has announced the inclusion of Pregabalin under Schedule H1 of the Drugs Rules, 1945, effective from May 13, 2026. This decision, published in the Gazette of India Extraordinary on May 20, 2026, aims to address the rising misuse and abuse of Pregabalin, particularly among the youth. The drug, used for treating chronic pain and certain neurological conditions, has been reported to be misused for its sedative and euphoric effects. The new classification imposes stricter regulations, requiring Pregabalin to be sold only with a valid prescription from a Registered Medical Practitioner (RMP). Retailers will need to maintain detailed records of prescriptions and sales, while manufacturers must display a 'Schedule H1 Drug Warning' label on packaging. Non-compliance with these regulations will attract penalties under the Drugs and Cosmetics Act of 1940. This initiative is part of a broader effort to enhance accountability in the drug supply chain and safeguard public health by preventing unauthorized access and curbing illegal trafficking.